Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Endocrinology & Diabetes ResearchISSN: 2470-7570
Marvin Rubenstein Author
Subjects of specialization
Affiliation
Antisense; Bcl-2; ,Androgen receptor; p300; Prostate cancer; Therapy
Colorado College, Indiana University Bloomington, Kansas City Art Institute, University of Texas at Austin
Biography
Gene therapy has now reached clinical trials for the treatment of human prostate tumors with antisense oligonucleotides (oligos) targeting Bcl-2 and clusterin, in efforts to restore apoptosis following radio- [1] or chemotherapy [2]. If such therapy is to be successful, it is important to examine mechanisms by which tumors compensate and become resistant.
Publications
Research Article Subscription
Multiple Pathways Compensate for Antisense Suppression of Bcl-2 in LNCaP Cells Contributing to Tumor Resistance
Author(s): Marvin Rubenstein, Courtney M. P. Hollowell and Patrick Guinan
Multiple Pathways Compensate for Antisense Suppression of Bcl-2 in LNCaP Cells Contributing to Tumor Resistance
Antisense oligonucleotides (oligos) have been employed against in vivo and in vitro prostate cancer models targeting growth regulatory proteins. While most oligos target growth factors or their receptors, others are directed against apoptosis inhibitors and mediators of androgen action. Those which suppress Bcl-2 activity have even reached clinical trials in prostate cancer patients. We previously evaluated a set of oligos which targeted and comparably suppressed the expression of the apoptosis inhibitor protein Bcl-2. LNCaP cells adapted to this restoration of apoptosis with suppression of caspase-3 (another apoptosis inhibitor). In this continuing ... view more»
Social Media
Google Scholars / Researchers Sites
